ASCP Presentation: DT-101 | a Novel AMPAR PAM Demonstrating Favorable Tolerability, PK and Target Engagement in Phase 1 Healthy Volunteer Trial

ASCP Poster Presentation: DT-101 – A Novel AMPAR PAM Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial

ASCP Poster Presentation: Magnetoencephalography (MEG) in a First-in-Human Trial toDemonstrate the Functional Consequences of Target Engagement by DT-101,a Novel AMPA Receptor Positive Allosteric Modulator